Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Panayotis Ledakis (NPI 1649385634)

Field	Value
Entity Type	Individual
Organization	Panayotis Ledakis
Address	227 St Paul Place
City	Baltimore
State	MD
ZIP	21202
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 20, 2006

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This provider’s Medicare business is highly concentrated in a small set of oncology drugs: the top 3 Medicare codes (J9271, J9299, J0897) account for 81.2% of total Medicare revenue. Lifetime Medicare revenue is $3M and those three drug codes together dominate the payer relationship, signaling dependence on high-cost oncologic infusions for revenue generation.

Code-level detail shows pembrolizumab (J9271) is the single largest revenue driver with $1.4M in Medicare revenue and 33.6K claims; this provider ranks #78 of 1841 nationally (96th percentile) and is described as notably above typical national volume for this code. Nivolumab (J9299) contributes $558.7K across 23.3K claims and ranks #124 of 505 (76th percentile), a typical national volume position, while denosumab (J0897) generates $354.2K from 19.7K claims and ranks #299 of 10057 (97th percentile), also notably above typical national volume.

The procedure mix and claim counts indicate an infusion-centric oncology practice: there are 632 claims for chemotherapy administration (96413, $68.3K revenue), 746 claims for IV push follow-on doses (96375, $9.7K), and multiple other infusion-related codes such as 96372 (624 claims, $6.9K) and 96365 (232 claims, $12.3K). These volumes are consistent with an outpatient infusion suite model that administers checkpoint inhibitors and supportive agents rather than a clinic focused only on office-based management.

Supportive-care biologics are a visible secondary line of business: pegfilgrastim (J2506) shows 984 claims and $82.7K in Medicare revenue with a national rank of #33 of 586 (95th percentile), flagged as notably above typical national volume, and darbepoetin alfa (J0881) appears with 39.1K claims and $78.2K revenue (rank #114 of 1114, 90th percentile). This pattern reinforces a combined oncology and supportive-care service line that manages chemotherapy-induced neutropenia and anemia.

Clinical E/M activity includes a heavy share of higher-complexity office visits: 99214 has 1.4K claims and $124.4K revenue and is flagged as an extreme outlier (rank #4488 of 479517, 99th percentile), while 99205 and 99215 also appear among the top codes (162 claims/$25.3K and 135 claims/$16.7K respectively). The unusually high relative volume for 99214 suggests frequent complex follow-up visits accompanying infusion services, rather than a minimal consult-only practice.

Competitive standing is mixed by code: the provider is a strong national performer for J9271 (96th percentile) and J0897 (97th percentile), indicating market-leading activity for those specific oncology drugs, while activity for J9299 sits at a more typical 76th percentile. Several infusion and supportive codes (for example J2506 at the 95th percentile and 96413 at the 95th percentile) further indicate the provider operates at above-typical scale in selected Medicare oncology services.

Payer mix is effectively single-payer on file: Medicare is the only recorded payer with $3M in lifetime revenue and there is explicitly no Medicaid billing on file. From a contracting and risk perspective, the provider is therefore functionally Medicare-dependent and has no Medicaid revenue to offset Medicare exposure.

Tenure and registration history show an established practice footprint: the NPI was enumerated on 2006-08-20 (~20 years ago), indicating long-standing Medicare participation that aligns with the sustained high volumes in oncology infusions and supportive-care biologics reported above.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	33,600	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	23,280	$20	$558.7K
J0897	Injection, denosumab, 1 mg	19,680	$20	$354.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,400	$90	$124.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	980	$80	$82.7K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	39,100	$1	$78.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$110	$68.3K
J2796	Injection, romiplostim, 10 micrograms	850	$70	$62.1K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	160	$160	$25.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	140	$120	$16.7K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Panayotis Ledakis — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	60	15,000	$40	$787.6K
J9299	13	20	24,080	$20	$660.6K
J2796	2	10	3,450	$70	$252.3K
J0897	21	340	3,600	$20	$114.4K
J0881	22	60	30,420	$1	$76.4K
J3490	41	100	70	$450	$62.1K
J2506	4	30	590	$80	$55.2K
96413	21	230	200	$110	$29.6K
J9217	97	100	150	$130	$27.3K
99214	201	10,270	150	$90	$24.1K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Panayotis Ledakis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St Paul Place Specialists, Inc.	MD	Dermatology Physician	$0	$13.3M
Michael Morris	MD	Diagnostic Radiology Physician	$12M	$0
Richard Huslig	MD	Hematology & Oncology Physician	$4.9M	$0
St Paul Place Specialists, Inc.	MD	Clinical Pathology/Laboratory Medicine Physician	$2.7M	$948.8K
Jaideep Sohi	IL	Nuclear Radiology Physician	$1.5M	$6.9K
Kelly Orwat	SC	Internal Medicine Physician	$1.3M	$0
Jonathan Breslau	MN	Diagnostic Radiology Physician	$1.3M	$0
Muhammad Saad Khan	IL	Hematology & Oncology Physician	$1.3M	$0
Stephen Ronson	MD	Specialist	$1.2M	$0
Pavni Patel	MD	Nuclear Medicine Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Panayotis Ledakis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Baltimore City Schools	MD	Local Education Agency (LEA)	$0	$95.8M
Mayor And City Council Of Baltimore	MD	Land Ambulance	$6.3M	$38M
Health Care For The Homeless, Inc	MD	Federally Qualified Health Center (FQHC)	$0	$26.8M
Maryland Family Care, Inc.	MD	Family Medicine Physician	$0	$24.6M
Hope Resource Center, LLC	MD	Community/Behavioral Health Agency	$0	$18.1M
Pha Healthcare LLC	MD	Substance Use Disorder Rehabilitation Clinic/Center	$0	$18M
Lighthouse Behavioral Health Center, LLC	MD	Substance Abuse Rehabilitation Facility	$0	$11.5M
Emergency Physicians Spps	MD	Emergency Medicine Physician	$0	$9.8M
Heavens Place-outpatient Detox & Recovery Center	MD	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$7.6M
S K Pesis Dds, Big Smiles Maryland, PC	MD	Dentist	$0	$6.9M

Panayotis Ledakis — Billing Profile & Reimbursement Data

Sign up for Panayotis Ledakis — Billing Profile & Reimbursement Data policy alerts

Panayotis Ledakis — Billing Profile & Reimbursement Data

Sign up for Panayotis Ledakis — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References